Keywords: Jazz Pharma, EUSA Pharma, M&S, Erwinaze, Leukemia
Jazz Pharma to acquire EUSA Pharma for up to $700 million
Article | 29 April 2012
US drugmaker Jazz Pharmaceuticals (Nasdaq: JAZZ) said last week that it has signed a definitive accord to acquire privately-held, UK-headquartered ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
